Ceftriaxone how supplied

Ceftriaxone
CEFTRIAXONE®,ROCEPHIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
Clinical Studies
Compatibility and Stability
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Ceftriaxone for Injection, USP is supplied as a sterile crystalline powder in glass vials. The following packages are available:

Bulk pharmacy containers, containing 10 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-0679-5). NOT FOR DIRECT ADMINISTRATION.

OTHER SIZE PACKAGE AVAILABLE Vials containing 250 mg equivalent of ceftriaxone. Box of 1 (NDC 60505-0750-0) and box of 10 (NDC 60505-0750-4).

Vials containing 500 mg equivalent of ceftriaxone. Box of 1 (NDC 60505-0751-0) and box of 10 (NDC 60505-0751-4).

Vials containing 1 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-0752-0) and box of 10 (NDC 60505-0752-4).

Vials containing 2 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-0753-0) and box of 10 (NDC 60505-0753-4).

Piggyback bottles containing 1 gm equivalent of ceftriaxone. Box of 1(NDC 60505-6087-1).

Piggyback bottles containing 2 gm equivalent of ceftriaxone. Box of 1(NDC 60505-6088-1).

NOTE: Ceftriaxone for Injection,USP sterile powder should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature] and protected from light.

Flagyl® is a registered trademark of G.D. Searle LLC.

References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/050796lbl.pdf